Welcome to our dedicated page for Renovorx SEC filings (Ticker: RNXT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
RenovoRx, Inc. filings document the regulatory record of a life-sciences company commercializing RenovoCath® and developing targeted oncology therapies through its TAMP™ platform. Periodic and current reports disclose operating results, commercialization updates, clinical-trial strategy, and business updates related to the company’s investigational IAG drug-device candidate.
The company’s SEC record includes 8-K filings for financial results, material agreements, equity financings, warrant instruments, and at-the-market offering arrangements. Proxy materials cover annual meeting matters, board governance, executive compensation, and shareholder voting items, while leadership-related filings document officer appointments, compensatory arrangements, and reporting responsibilities.
RenovoRx, Inc. Chief Financial Officer Mark Voll, through the Voll Family Trust, reported buying both common stock and warrants in a private placement. The trust acquired 97,200 shares of common stock and 48,600 warrants, for an aggregate purchase price of $100,000.
The warrants are exercisable immediately at $1.9326 per share of underlying common stock and will expire on the earlier of March 30, 2029 or 30 days after RenovoRx reports at least $1.5 million in product sales revenue for any calendar quarter.
RenovoRx, Inc. filed an initial ownership report for company executive Mark Voll. The filing shows he directly holds 25,000 shares of RenovoRx common stock. A footnote explains these securities were purchased in open-market transactions before his appointment to a senior executive role at the company.
RenovoRx, Inc. entered into a private placement with 15 accredited and institutional investors, including company insiders, raising approximately $10 million in gross proceeds. The company sold 8,438,790 shares of common stock, pre-funded warrants for 2,200,000 shares, and revenue milestone warrants for 5,319,392 shares.
Institutional investors paid $0.938 per share and related milestone warrant, while insiders paid $1.0288 to comply with Nasdaq rules. The milestone warrants are immediately exercisable at $1.751 per share for institutions and $1.9326 for insiders, and expire on the earlier of March 30, 2029 or 30 days after RenovoRx reports at least $1.5 million in product sales revenue for a quarter.
RenovoRx agreed to file and seek effectiveness of a resale registration statement for the shares and warrant shares within specified timelines, with cash liquidated damages of up to 10% of each investor’s subscription amount if deadlines are missed. The company plans to use proceeds to support commercialization of its RenovoCath device and advance its Phase III TIGeR-PaC trial.
RenovoRx, Inc. announced leadership changes in its finance organization and highlighted early commercial traction for its RenovoCath device. Principal Accounting Officer Ronald B. Kocak resigned from that role on February 3, 2026, but remains Vice President and Controller with his 2026 salary unchanged.
On February 4, 2026, the board appointed consultant Mark Voll as Chief Financial Officer, serving as the company’s principal financial and accounting officer. Under a consulting agreement, he is paid $250 per hour, half in cash and half in restricted stock units, and is eligible for an initial grant of 60,000 RSUs under the 2021 Omnibus Equity Incentive Plan. A related press release notes that RenovoRx generated approximately $900,000 of RenovoCath sales revenue in the first nine months of 2025 as it transitions from purely clinical-stage activities toward commercialization.
AIGH Capital Management LLC and Orin Hirschman report a 7.1% ownership stake in Renovorx, Inc. common stock on a Schedule 13G/A (Amendment No. 2). They report beneficial ownership of 2,615,193 shares, with sole voting and sole dispositive power over all of these shares and no shared power.
The filing identifies AIGH Capital Management LLC, AIGH Investment Partners LLC, and Orin Hirschman as the reporting persons, with Hirschman serving as managing member and president of the related entities. The securities are certified as acquired and held in the ordinary course of business, and not for the purpose of changing or influencing control of Renovorx.
RenovoRx, Inc. Chief Medical Officer and director Ramtin Agah reported an open market purchase of the company’s common stock. On January 21, 2026, he bought 10,000 shares of RenovoRx common stock in open market transactions at a weighted average price of $0.9975 per share. The filing notes that the shares were acquired in multiple trades at prices ranging from $0.995 to $1.00 per share. Following this purchase, Agah directly holds 798,460 shares of RenovoRx common stock.
RenovoRx, Inc. director and Chief Medical Officer Ramtin Agah reported buying 12,000 shares of the company’s common stock in an open market transaction on December 16, 2025, at a price of $0.85 per share.
After this purchase, he beneficially owns 778,460 shares of RenovoRx common stock, held directly. Agah serves as both a director and an officer, so this transaction increases his personal equity stake alongside his leadership responsibilities at the company.
RenovoRx, Inc. insider trading report: Director and Chief Medical Officer Ramtin Agah reported open market purchases of RenovoRx common stock. On 11/21/2025, he bought 10,000 shares at a price of $0.80 per share, and on 11/24/2025 he purchased an additional 12,000 shares at $0.80 per share. After these transactions, he beneficially owned 756,460 shares of RenovoRx common stock, held directly. The filing notes that these transactions reflect open market purchases of the company’s securities.
RenovoRx, Inc. entered into a Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC, allowing it to issue and sell up to $3,723,029 of common stock from time to time in at-the-market offerings or negotiated transactions. JonesTrading will act as sales agent or principal and may receive a commission of up to 3.0% of the gross sales price of any shares sold. The shares will be offered under RenovoRx’s existing Form S-3 shelf registration statement, and a newly filed Form S-3 allows continued use of that shelf for an additional 180 days past its November 21, 2025 expiration.
RenovoRx, Inc. is launching an at-the-market stock offering of up to $3,723,029 of common shares through JonesTrading. The company may sell shares from time to time, with JonesTrading acting as agent or principal and earning up to a 3% commission on gross proceeds. An illustrative scenario assumes 3,479,466 shares sold at $1.07 per share, which would increase shares outstanding from 36,649,916 to 40,129,382.
RenovoRx plans to use the net proceeds for working capital and general corporate purposes, including its Phase III TIGeR-PaC study of its IAG drug–device combination and commercialization of its FDA-cleared RenovoCath delivery device. The company is a commercial and clinical stage life sciences business focused on targeted intra-arterial chemotherapy using its TAMP platform, and is also running a post-marketing RR5 registry to evaluate RenovoCath in solid tumors.